PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM
May 1, 2009, 00:00
10.1016/S1098-3015(10)73253-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)73253-8/fulltext
Title :
PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73253-8&doi=10.1016/S1098-3015(10)73253-8
First page :
Section Title :
Open access? :
No
Section Order :
673